The mission of NuSomnea is to revolutionize the diagnosis and management of Obstructive Sleep Apnea (OSA) by replacing overnight sleep tests with a simpler, easier, less costly and more accurate test.
The NuSomnea test involves the assay of multiple urinary peptide biomarkers, providing comparable or greater accuracy for OSA diagnosis than the standard polysomnography (PSG) procedure. A prospective, controlled, proof-of-concept study conducted in 120 pediatric subjects has demonstrated 100% sensitivity and 96.5% specificity for diagnosing OSA.
Because the cost is significantly lower and the ease of administration is significantly more convenient than that of a PSG, this new test can be utilized globally as both a diagnostic tool and a disease management tool, to monitor therapy effectiveness and improve patient outcomes.
The company has secured the exclusive intellectual property rights for the assay. Because one of the co-founders is already a CLIA-certified lab, NuSomnea will be able to rapidly refine, validate and introduce this test. Using the reference lab as an initial business model will also provide greater flexibility for commercialization and distribution of the tests.
NuSomnea is revolutionizing the diagnosis and management of Obstructive Sleep Apnea (OSA) by eliminating the need for overnight sleep tests. For detailed information regarding our corporate direction, including our Executive Summary, Business Plan and Investor Presentation, click on a thumbnail below to fill out our brief contact form. We’ll quickly deliver our Corporate Information Packet.
|Pediatric Medicine’s Damaging Oversight
The superabundance of ADHD diagnoses in children today may be caused by a damaging oversight: Undiagnosed sleep disorders, often linked to obesity in children, present identical symptoms.
|WSJS Radio Interview with NuSomnea Co-Founder, Mike Thomas and Medical Director, Dr. Jon Freudman
Tuesday, October 7, 2014, www.wsjs.com
|What If Sleep Apnea Is to Blame?
Sleep problems are among the most persistent and maddening ones we face. One startup company is aiming to change that with a new, inexpensive test to see whether your child’s inattention and hyperactivity actually stem from sleep apnea, not ADHD.
|Innovative Urine Test Detects Pediatric Sleep Disorder Often Misdiagnosed as ADHD
NuSomnea launches crowdfunding campaign in time for Sleep Apnea Awareness Week and ADHD Awareness Month.
|It’s Easy Peezy – Pee Test Detects Pediatric Sleep Disorder with ADHD
NuSomnea launches crowdfunding campaign to bring innovative pee test to market.
|New Test Helps Diagnose Pediatric Sleep Disorder Often Mistaken for ADHD
Innovator of Easy Peezy Pee Test says nearly 2.5 million kids diagnosed with ADHD may actually have Obstructive Sleep Apnea.
Mike Thomas CEO
Co-Founder, Executive Chairman
Mr. Thomas is the former CEO of iSonea Ltd (ASX:ISN), a publicly traded global, mobile health app developer and medical device manufacturer in the respiratory disease market. He is a member of the Board of Directors for Circadiance LLC, a specialty CPAP mask manufacturer. He is also the President and CEO of Appian Partners, a medical devices and healthcare services consulting firm. Earlier in his career, Thomas was President and CEO of Sleep Solutions, a VC-backed medical device manufacturer. He raised over $50 million in VC funding for that company and launch a new industry in the $5B Sleep Medicine market. Thomas successfully lobbied the largest Managed Care Organizations (MCOs) and the Centers for Medicare and Medicaid Services (CMS) to alter their medical policy and approve reimbursement for in-home sleep apnea diagnostic services. Prior to joining Sleep Solutions, Thomas was EVP of Sales and Marketing for National Sleep Technologies (NST), where he led acquisitions of more than 80 sleep labs, making NST the largest sleep-testing company in the US. NST was later sold to GE Medical. Earlier in his career, Thomas was Vice President of Sales at Patient InfoSystems (NASDAQ: PATI) and instrumental in taking that company public. He began his career in sales and marketing at Merck and GlaxoWellcome. Thomas graduated from Cornell University with a degree in Microbiology.
Roland Valdes, PhD, DABCC, FACB
Chief Science Officer, Co-Founder
Dr. Valdes is Senior Vice-Chairman of the Department of Pathology and Laboratory Medicine at the University of Louisville. He is also Professor of Biochemistry and Molecular Biology and holds the appointment of Distinguished University Scholar. Dr. Valdes serves as Director of Clinical Chemistry and Toxicology and as Director of the Postdoctoral Fellowship Program in Clinical Chemistry and Laboratory Medicine in the Department of Pathology. Dr. Valdes’ efforts are now directed toward bringing the sciences of pharmacogenetics and proteomics into clinical laboratory practice. He is a Fellow and past-President of the National Academy of Clinical Biochemistry, and past-President of the Clinical Ligand Assay Society. He also holds several Distinguished Scientist Awards, has authored over 230 publications in the scientific literature, and has mentored, to date, more than 30 trainees in laboratory medicine and research. He is presently chair of a national committee establishing practice guidelines in pharmacogenetics. He is co-founder, Chairman and President of PGXL Laboratories and PGXL Technologies.
Mark Linder, PhD, PhD, DABCC, FACB
VP Research and Development, Co-Founder
Dr. Linder is Professor of the Department of Pathology and Laboratory Medicine at the University of Louisville. He is a Director of Clinical Chemistry and Toxicology at the University of Louisville Hospital. As the Executive V.P. for Operations for PGXL Laboratories and PGXL Technologies, he oversees clinical studies conducted by the companies and is responsible for the operation of the CLIA lab. Dr. Linder has been actively involved in pharmacogenetics research and translation of that research into clinical services. He is a Fellow of the National Academy of Clinical Biochemistry (NACB) and serves on a number of committees for the American Association for Clinical Chemistry (AACC). His scientific interests include mechanisms for regulation of drug metabolism and bringing the science of both pharmacogenetics and proteomics into clinical laboratory practice. Dr. Linder is a thought leader in the new field of pharmacogenetics, having developed several pharmacogenetic tests now being used by PGXL. He is the principal inventor of PerMIT, a companion informatic software currently in clinical trials.
Send us your information and receive more information about NuSomnea. Fill out our form and we will email you our Executive Summary, Business Plan and Investor Presentation.